Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AMD$490.38+6.55(+1.35%)Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains10:20:05 AM ETCL$98.34+2.74(+2.87%)Inflation Is Running Above 3%. These 3 Dividend Stocks Have the Pricing Power to Keep Up.10:17:41 AM ETMU$823.14-31.79(-3.72%)Micron and other chip stocks slip as election results strike at the core of data-center optimism10:17:00 AM ETSHEL$103.90-0.32(-0.31%)Shell Agrees to $1.45 Billion Sale of North West Shelf Stake10:16:15 AM ETQCOM$168.33+3.90(+2.37%)Qualcomm sat out the semiconductor rally. Can a SpaceX partnership change that?10:13:00 AM ETAVGO$328.68-3.41(-1.03%)One Wall Street Analyst Says This Stock Is the Best Way to Invest in Anthropic and OpenAI. He's Right.10:10:00 AM ETSNDK$1,073.66-52.86(-4.69%)Sandisk Is Retiring Its Own Stock At A Discount - Upgrade To Buy10:08:39 AM ETMSFT$552.55+31.77(+6.10%)If You Invest $1,000 in Microsoft Today, Here's What It Could Be Worth by 202910:06:14 AM ETORCL$126.62+0.40(+0.32%)Oracle stock in green despite reported $7B Tencent chip deal cancellation10:03:17 AM ETAAPL$353.08+21.44(+6.46%)Amazon Rallies 7%, Apple and Microsoft Climb 5% as Big Tech Leads Post-Election Rebound10:02:35 AM ETJPM$345.47+7.55(+2.23%)How Will Automation and Kinexys Drive JPMorgan's Payments Growth?10:01:30 AM ETGS$912.01+16.16(+1.80%)The Goldman Sachs Group, Inc. (GS) is Attracting Investor Attention: Here is What You Should Know10:01:23 AM ETKO$94.70-0.09(-0.09%)CocaCola Company (The) (KO) Is a Trending Stock: Facts to Know Before Betting on It10:01:14 AM ETGILD$169.22+1.76(+1.05%)Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It10:01:13 AM ETWFC$85.60+0.07(+0.08%)Here is What to Know Beyond Why Wells Fargo & Company (WFC) is a Trending Stock10:01:11 AM ETABBV$285.16-0.81(-0.28%)Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?10:01:07 AM ETASML$1,512.05-39.73(-2.56%)ASML Holding N.V. (ASML) Is a Trending Stock: Facts to Know Before Betting on It10:01:05 AM ETQCOM$168.33+3.90(+2.37%)Options Corner: QCOM Signs SPCX Deal as Earnings Loom10:00:04 AM ETAMZN$268.35+17.57(+7.01%)Amazon Stock Fell After Earnings. Should Investors Be Worried?10:00:00 AM ETASML$1,512.05-39.73(-2.56%)Better AI Semiconductor Monopoly Stock: Taiwan Semiconductor vs. ASML9:55:00 AM ETAMD$490.38+6.55(+1.35%)AMD Just Doubled Its Own Long-Term Growth Target for 20279:54:15 AM ETWMT$128.54+3.70(+2.96%)As Holidays Approach, No One Cares About Amazon's Biggest Business9:45:51 AM ETQCOM$168.33+3.90(+2.37%)Qualcomm Shares Rise Wednesday: What's Going On?9:38:42 AM ETASM$4.56+0.30(+7.04%)ASM International: 1.4nm Could Keep The Growth Going9:36:39 AM ET

XBIO · NASDAQ

Xenetic Biosciences, Inc.

$2.06 +0.06 (+3.00%)

Company overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$4.8M
Employees
2
Headquarters
Framingham, MA
Website
xeneticbio.com
CEO
James F. Parslow
Listed
June 30, 2016
P/E
-1.67
Dividend yield
0.00%

Company financials

Revenue
$3.2M
Gross profit
$3.2M
Operating income
-$2.4M
EBITDA
-$2.4M
Net income
-$2.2M
EPS
-$1.23
Total assets
$7.9M
Total debt
$0.00
Gross margin
100.00%
Net margin
-70.03%
Earnings yield
-59.71%

Revenue segmentation

By product (FY 2020)
By region (FY 2020)

No geographic segmentation.

Showing FY 2020

Price chart

1.452.353.264.175.07
XBIO 1D NASDAQ O2.06H2.13L2.00C2.00-0.06 (-2.91%)Vol6.44K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance ACCESS Newswire
XBIOXenetic Biosciences, Inc. Stock news Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis Defense World
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma ACCESS Newswire
XBIOXenetic Biosciences, Inc. Stock news Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR) Defense World
XBIOXenetic Biosciences, Inc. Stock news Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript Seeking Alpha
XBIOXenetic Biosciences, Inc. Stock news Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition Benzinga
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics Accesswire
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform Accesswire
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-C… Accesswire
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival Accesswire
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform Accesswire
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting Accesswire
XBIOXenetic Biosciences, Inc. Stock news Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast Defense World
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results Accesswire
XBIOXenetic Biosciences, Inc. Stock news Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis Defense World
XBIOXenetic Biosciences, Inc. Stock news Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest Defense World
XBIOXenetic Biosciences, Inc. Stock news Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO) Defense World
XBIOXenetic Biosciences, Inc. Stock news Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX) Defense World
XBIOXenetic Biosciences, Inc. Stock news Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest Defense World
XBIOXenetic Biosciences, Inc. Press release Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Accesswire
See more
FAQ

Questions about Xenetic Biosciences, Inc.

What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
What is XBIO's market cap?
Xenetic Biosciences, Inc. (XBIO) is a listed stock with a live quote. The latest market cap on this page is $4.8M.
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. is headquartered in Framingham, MA.
How do I get XBIO news from the API?
Call GET /v1/news?tickers=XBIO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does XBIO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for XBIO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the XBIO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs